Trials / Completed
CompletedNCT00744991
A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
A Phase 2, Open-Label, Multicenter Study of Single-Agent Enzastaurin in Patients With Relapsed Cutaneous T-Cell Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine the efficacy and safety of enzastaurin in participants with Cutaneous T-Cell Lymphoma (CTCL) who failed prior therapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enzastaurin | 1125 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2010-01-01
- Completion
- 2010-02-01
- First posted
- 2008-09-01
- Last updated
- 2020-10-19
- Results posted
- 2020-10-19
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00744991. Inclusion in this directory is not an endorsement.